



Medicine Supply Notification

MSN/2025/036U2

UPDATE to communication (MSN/2025/036U) issued on 14 August 2025.

Levemir® products are being discontinued. Stock exhaustion is expected in December 2026. This notification is being re-issued, as a high number of patients remain on Levemir® products. Healthcare professionals are reminded to switch patients on Levemir® to a suitable alternative as soon as possible. Patients should be switched as per guidance below.

Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and

Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges

Tier 2 – medium impact*

Date of issue: 15/04/2026

Link: [Medicines Supply Tool](#)

Summary

- Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges are being discontinued; stock is anticipated to be exhausted by the end of 2026.
- [Clinical guidance](#) has been produced by clinical experts (see Supporting information).
- Current supply positions and ability of alternative insulins to support an increase in demand is summarised below. Any changes to availability will be communicated via the [SPS Medicines Supply Tool](#).

Actions Required

Clinicians should:

- not initiate new patients on any Levemir® product; and
- begin implementing insulin switches for all existing Levemir® patients in line with the [clinical guidance](#) (see Supporting information).

Local teams should ensure that they have checked the current supply overview of alternative insulins to reduce the risk of precipitating a supply disruption of alternative products (see Supporting information).

As recommended in the [clinical guidance](#), clinicians should aim to diversify prescribing across available alternatives to reduce supply risk where possible.

In addition to consulting the [clinical guidance](#), when prescribing alternatives, consider manual dexterity, vision, and whether additional support is required for administration, and:

- ensure that all patients/carers are counselled on dose to be administered, provided with training on the use of their new device, as well as appropriate ancillaries, including signposting to training videos; and

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

- advise patients that closer monitoring of blood glucose levels is required initially, and their insulin dose may need to be adjusted.

Seek advice from specialist diabetes teams where required.

Supporting information

Supply summary table

Levemir® is a long-acting insulin analogue with a prolonged duration of effect used as a basal insulin. It is licensed for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. It can be used alone as the basal insulin or in combination with bolus insulin. It can also be used in combination with oral antidiabetic medicinal products and/or GLP-1 receptor agonists.

As insulin glargine is available in two strengths, these products must be prescribed BY BRAND to minimise the risk of product mis-selection.

Insulin type		Supply overview	
Insulin type	Brand name and devices	Stock status	Ability to support increased demand
Insulin glargine U100 (Long acting)	Abasaglar® KwikPen®	In stock	Cannot support
	Abasaglar® cartridges	In stock	Cannot support
	Lantus® SoloStar®	In stock	Can support
	Lantus® cartridges	In stock	Can support
	Semglee® pre-filled pens (biosimilar)	In stock	Can support
Insulin glargine U300 (Ultralong acting)	Toujeo® SoloStar®	In stock	Can support
	Toujeo® DoubleStar®	In stock	Can support
Insulin degludec (Ultralong acting)	Tresiba® U100 FlexTouch®	Discontinued	
	Tresiba® U100 cartridges	In stock	Can support
	Tresiba® U200 FlexTouch®	In stock	Can support
Human isophane insulin (intermediate acting)	Humulin® I KwikPen®	In stock	Cannot support
	Humulin® I cartridges	In stock	Cannot support

Links to further information

[Clinical Guideline: Discontinuation of Levemir®](#)
[BNF Insulin detemir](#)
[BNF Insulin preparations](#)
[NICE guidance: Type 1 diabetes in adults \(insulin therapy\)](#)
[NICE CKS- Insulin therapy in type 1 diabetes](#)
[NICE CKS- Insulin therapy in type 2 diabetes](#)

[SmPC Levemir®](#)
[SmPC Lantus®](#)
[SmPC Toujeo®](#)
[SmPC Abasaglar®](#)
[SmPC Semglee®](#)
[SmPC Tresiba®](#)
[SmPC Humulin® I](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.